Adaptive Biotechnologies projected robust growth for its minimal residual disease (MRD) business in 2026, guiding MRD revenue to $255–$265 million and forecasting a roughly 30% increase in ClonoSeq test volumes. Management said pricing and deeper penetration into community clinical settings, alongside growing regulatory and clinical endorsement of MRD as an endpoint, will drive revenue expansion. The company plans to scale MRD services for registrational oncology trials and expects MRD to underpin both clinical testing and biopharma trial services. Adaptive’s update signals diagnostics firms are commercializing emerging biomarkers into sustained revenue streams.